Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects

Digestive and Liver Disease

Volumn 33, Issue SUPPL. 2, 2001, Pages

  Lazzaroni, M ^a   Bianchi Porro, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

H2 blockers; Helicobacter pylori; Misoprostol; NSAIDs; Proton pump inhibitors; Sucralfate

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; ANTACID AGENT; ARTHROTEC; CIMETIDINE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; TETRACYCLINE;

ABDOMINAL PAIN; ARTICLE; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; FOLLOW UP; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HUMAN; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH ULCER; ULCER HEALING; UPPER GASTROINTESTINAL TRACT; UTERUS CONTRACTILITY;

EID: 0035669912     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80158-4     Document Type: Article

References (137)

1. Non-steroidal anti-inflammatory drugs
2. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study
3. From prostaglandin replacement to specific COX-2 inhibition. A critical appraisal
4. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. A randomized, double blind placebo controlled trial
5. FDA Arthritis Advisory Committee meeting: Serious gastrointestinal toxicity of non-steroidal anti-inflammatory drugs
6. Epidemiology of NSAID-induced GI complications
7. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs
8. NSAID gastropathy, epidemiology
9. Recent considerations in non-steroidal anti-inflammatory drug gastropathy
10. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: A meta analysis
11. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice
12. Guidelines for medical management of osteoarthritis. Part I. Osteoarthritis of the hip
13. Guidelines for medical management of osteoarthritis. Part II. Osteoarthritis of the knee
14. Guidelines for the management of rheumatoid arthritis
15. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double blind, placebo, controlled trial
16. Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs
17. Misoprostol dosage for the prevention of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens
18. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials
19. Non-steroidal anti-inflammatory drug gastropathy: Clinical results with misoprostol
20. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: Risk factors for serious complications
21. Randomized trial of low-dose misoprostol and naproxen vs nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs
22. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury
23. A double blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misprostol in the treatment of rheumatoid arthritis
24. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: A randomized, placebo controlled trial
25. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury: Effect of scoring method
26. Protective effect of sucralfate against aspirin-induced damage to the human gastric mucosa
27. Gastroprotection by sucralfate against acetylsalicylic acid in humans. Role of endogenous prostaglandins
28. Protection of gastric mucosa by sucralfate from aspirin-induced erosions
29. Does sucralfate reduce acetylsalicylic acid induced gastric mucosal bleeding?
30. Sucralfate for prevention of naproxen induced mucosal lesions in the proximal and distal gastrointestinal tract
31. Does sucralfate protect against aspirin induced mucosal lesions? Yes and no
32. Lack of gastric mucosal protection by sucralfate during long term aspirin ingestion in humans
33. Gastric adaptation occurs with aspirin administration in man
34. Does sucralfate prevent short-term NSAID induced damage of gastroduodenal mucosa?
35. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration
36. Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug-induced gastric ulcer
37. Sucralfate treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage
38. Antacids and gastric mucosa protection
39. Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment
40. Are antacids cytoprotective?
41. Morphologic and ultrastructural effects of MaaloxTc on human gastric and duodenal mucosa
42. Putative mechanisms of cytoprotective effect of certain antacids and sucralfate
43. Intragastric pH in the gastroprotective and ulcer-healing activity of aluminium-containing antacids
44. 2-blokkern, Prostaglandinen und Omeprazole
45. Acute damage of gastroduodenal mucosa by acetylsalicylic acid: No prolonged protection by antacids
46. Low-dose antacids and non-steroidal anti-inflammatory drug-induced gastropathy in humans
47. 2 receptor blockers in the prevention of gastric injury resulting from non-steroidal anti-inflammatory agents
48. Cimetidine tablets or suspension for the prevention of gastrointestinal mucosal lesions caused by non-steroidal anti-inflammatory drugs
49. Reduction of aspirin induced gastroduodenal mucosal damage with ranitidine
50. NSAID-associated gastroduodenal damage: Does famotidine protection extend into the mid and distal duodenum?
51. Double blind placebo controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin induced mucosal injury to the stomach and duodenum
52. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen
53. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients
54. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
55. Why are non-steroidal anti-inflammatory drugs important in peptic ulceration?
56. Effect of ranitidine on gastroduodenal mucosal damage induced by non-steroidal anti-inflammatory drugs
57. Nizatidine prevents peptic ulceration in high risk patients taking non-steroidal anti-inflammatory drugs
58. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double blind, multicenter study
59. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs
60. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs
61. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs
62. Famotidine for healing and maintenance in non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration
63. Acute gastric bleeding from aspirin
64. Abolition by omeprazole of aspirin induced gastric mucosal injury in man
65. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study
66. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study
67. Omeprazole ameliorates aspirin-induced gastroduodenal injury
68. Efficacy of pantoprazole in the prevention of peptic ulcers induced by non-steroidal anti-inflammatory drugs: A prospective, placebo-controlled, double-blind, parallel-group study
69. Healing and prevention of NSAID associated ulcers in patients continuing to take NSAIDs-lansoprazole vs ranitidine and lansoprazole vs misoprostol vs placebo
70. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen
71. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs
72. Gastrointestinal tract complications and non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study
73. Prevention of severe acute NSAID-related gastroduodenal damage: A meta-analysis of controlled clinical trials
74. A guideline for the treatment and prevention of NSAID-induced ulcers
75. Non-steroidal anti-inflammatory drugs
76. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: An international multicenter collaborative study
77. The effect of ranitidine on NSAID-related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis or osteoarthritis
78. Sucralfate therapy of non-steroidal anti-inflammatory drug-induced gastritis
79. Effect of sucralfate and cimetidine on rheumatoid patients with active gastroduodenal lesions who are taking non-steroidal anti-inflammatory drugs
80. Randomized study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease
81. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer
82. Healing of peptic ulcers during continuing anti-inflammatory drug therapy in rheumatoid arthritis
83. Cimetidine in the treatment of gastric ulcer, induced by steroidal and non-steroidal anti-inflammatory agents
84. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin
85. The influence of cimetidine on peptic ulcers patients with arthritis taking anti-inflammatory drugs
86. Effect of famotidine on gastric ulcer healing. A comparison between non-steroidal and aspirin induced ulceration and idiopathic ulcers
87. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcer
88. Aspirin concurrently administered with ranitidine does not delay healing of duodenal ulcer
89. Cimetidine therapy in non-steroidal anti-inflammatory drug gastropathy
90. Healing of aspirin associated peptic ulcer disease despite continued salicylate ingestion
91. The influence of cimetidine on peptic ulcer patients with arthritis taking anti-inflammatory drugs
92. The effects of cimetidine on the healing of non-steroidal anti-inflammatory drug-induced gastroduodenal damage while continuing NSAID therapy
93. A placebo-controlled study of ranitidine in healing NSAID-associated gastric and duodenal ulcers
94. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer
95. Effectiveness of lansoprazole in the healing of NSAID-induced gastric ulcer in patients continuing to take NSAIDs
96. Does famotidine have the similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?
97. Prevention and treatment of non-steroidal gastroduodenal lesions
98. Helicobacter pylori: A risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy
99. Non-steroidal anti-inflammatory drugs (NSAID) cause gastrointestinal ulcers mainly in Helicobacter pylori carriers
100. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non steroidal anti-inflammatory drugs
101. Campylobacter pylori, NSAIDs, and smoking are risk factors for peptic ulcer disease
102. The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly
103. Campylobacter-like organisms, non-steroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis
104. Prevalence of Helicobacter pylori and its effect on symptoms and non-steroidal anti-inflammatory drug-induced gastrointestinal damage in patients with rheumatoid arthritis
105. The presence of Campylobacter pylori in non-steroidal anti-inflammatory drug associated gastritis
106. The influence of Helicobacter pylori colonisation and gastroduodenal ulceration in patients on non-steroidal anti-inflammatory drugs
107. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs
108. Long term non-steroidal anti-inflammatory drug use and Helicobacter pylori infection
109. Helicobacter pylori infection in elderly people: Correlation between histology and serology
110. Ulcer risk factors: Interactions between Helicobacter pylori infection, non-steroidal anti-inflammatory drug use and age
111. H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID) induced gastro-duodenal ulceration
112. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: Predisposition to ulceration and relation to H. pylori
113. No evidence of H. pylori-NSAID interaction in ulcer formation: Results of double blind, placebo controlled trials
114. Helicobacter pylori infection and the development of gastric and duodenal ulcer in arthritic patients receiving chronic NSAID therapy
115. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
116. Role of the Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy
117. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
118. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly patients
119. Can eradication of Helicobacter pylori prevent future development of peptic ulcers in patients receiving long-term continuous non-steroidal anti-inflammatory drugs?
120. Role of non steroidal anti-inflammatory drugs and Helicobacter pylori in bleeding peptic ulcer
121. Ulcer site and complications: Relation to Helicobacter pylori infection and NSAID use
122. The prevalence of Helicobacter pylori and NSAID use in patients with UGI haemorrhage and their potential role in recurrence of ulcer bleeding
123. Helicobacter pylori increases the risk of peptic ulcer bleeding: A case control study
124. Helicobacter pylori and acute bleeding peptic ulcer
125. Helicobacter pylori and risk of ulcer bleeding among users of non-steroidal anti-inflammatory drugs: A case control study
126. Non-steroidal anti-inflammatory drugs, Helicobacter pylori, and bleeding gastric ulcer
127. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: A case control study
128. The prevalence of Helicobacter pylori and NSAID use in patients with severe UGI haemorrhage and their potential role in recurrence of ulcer bleeding
129. Differing prevalence of Helicobacter in bleeding and non bleeding ulcers
130. Interaction of risk factors for peptic ulcer bleeding
131. Is Helicobacter pylori a risk factor for NSAID-associated gastric ulcer bleeding? A sex- and age-matched case-control study
132. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding
133. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
134. Eradication of H. pylori versus maintenance acid suppression to prevent recurrent haemorrhage in high risk NSAID users: A prospective randomized study
135. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection
136. What consideration should be given to Helicobacter pylori in treating non-steroidal anti-inflammatory drug ulcers?
137. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: A decision analysis